US Ebola patients get experimental drug
A SMALL San Diego-based company has provided an experimental Ebola drug for two Americans infected with the deadly virus in Liberia. The drug, produced using the tobacco plant, appears to be working.
In an unusual twist of expedited drug access, Mapp Biopharmaceutical, which has nine employees, released its experimental ZMapp drug - tested only on infected animals until now - to the two health workers.
The first patient, Kent Brantly, a doctor, was flown from Liberia to Atlanta on Saturday, and is receiving treatment at Emory University Hospital.
Aid worker Nancy Writebol was scheduled to arrive in Atlanta yesterday, and will be treated at the same hospital. Both are showing signs of improvement, according to relatives and supporters.
Each patient received at least one dose of ZMapp in Liberia before coming to the United States, according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
"There's a very scarce number of doses", and it is not clear how many each patient needs for treatment, he said.